The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Britain's Serious Fraud Office re-examines funding model

Tue, 24th May 2016 17:13

By Kirstin Ridley

LONDON, May 24 (Reuters) - The Serious Fraud Office (SFO),Britain's leading fraud and corruption investigator andprosecutor, said on Tuesday it was re-examining a funding modelthat has been criticised for risking weakening investigationsand delaying cases.

So-called "blockbuster funding", under which the agency canrequest extra cash for costly cases directly from thegovernment, was criticised in a report published on Tuesday bythe Crown Prosecution Service Inspectorate (CPSI), which reviewsthe effectiveness of the SFO's structures and governance.

The CPSI said such a model, which allows the SFO to shore upits staffing levels with external experts for big cases, coulddamage investigations, did not provide value for money andprevented the agency from building future expertise in-house.

It said that when it inspected the agency 21 percent ofstaff were not permanent employees.

"There is therefore an inherent lack of consistency in (SFO)teams, which becomes particularly problematic because of thelengthy nature of SFO investigations," the report said. "Thisdisruption increases the risk of delay in cases and may weakenthe investigative strategy going forward."

The CPSI report, which praised the SFO board for improvingthe reputation of the agency externally over the last fouryears, also suggested other reforms such as a smaller managementboard, appointing a chief executive, clearer reporting anddelegation lines for committees and holistic risk management.

SFO head David Green said in an emailed statement that theagency was "giving new consideration" to a funding model he hassaid in the past is not perfect, but which "does the job".

He said the SFO was also carefully considering recommendations such as appointing a CEO or chief operatingofficer and changing the structure of the management board.

Legal experts have already criticised a funding model theyargue could lead to political interference with cases that canconcern influential blue-chip British companies. The SFO'scurrent caseload includes investigations into Barclays,Rolls-Royce and GSK.

The SFO operates on a core annual budget of around 35million pounds ($51 mln), although extra cash injections to payfor costly cases have pushed that up to around 50 million poundsa year over the last few years.

Its biggest and costliest cases have included theinvestigation into the alleged manipulation of financialbenchmarks such as Libor (London interbank offered rate), whichto date has yielded one conviction and one guilty plea.

Five former Barclays traders are on trial at Southwark CrownCourt and further trials of individuals accused of manipulatingEuribor (euro interbank offered rate) are expected to begin nextyear. ($1 = 0.6838 pounds) (Reporting by Kirstin Ridley; Editing by Susan Fenton)

More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.